RIO DE JANEIRO, BRAZIL - A new Covid-19 vaccine candidate is being developed by Argentine and Brazilian researchers, searching for a vaccine focused on the new virus variants, such as the P.1, which is present in both countries.
The vaccine, developed in partnership with American biotech Vaxinz, showed positive results in tests with mice, pointing to the production of specific antibodies and immune system response against the novel coronavirus. The goal is to meet the demand for vaccines in Latin America, which still relies on raw materials and alternatives from other continents.
The project began with research by scientists . . .